Tetanus (Infectious Disease) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tetanus – Drugs In Development, 2021, provides an overview of the Tetanus (Infectious Disease) pipeline landscape.

Tetanus is a serious illness caused by Clostridium bacteria. Signs and symptoms of tetanus include spasms and stiffness in jaw muscles, difficulty swallowing, stiffness of abdominal muscles, fever, sweating, elevated blood pressure and rapid heart rate. The predisposing factors include burns, surgical wounds, ear infections, swelling around the injury and infected foot ulcers. Treatment includes antibiotics, sedatives and beta blockers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tetanus – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Tetanus (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tetanus (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tetanus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 11, 5, 11, 1, 13, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 1 and 1 molecules, respectively.

Tetanus (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Tetanus (Infectious Disease).

– The pipeline guide reviews pipeline therapeutics for Tetanus (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Tetanus (Infectious Disease) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Tetanus (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Tetanus (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Tetanus (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Tetanus (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

AIM Vaccine Co Ltd

Beijing Minhai Biotechnology Co Ltd

Beijing Tiantan Biological Products Co Ltd

Biken Co Ltd

Biological E Ltd

BioNet-Asia Co Ltd

Boryung Pharmaceutical Co Ltd

Cadila Healthcare Ltd

CanSino Biologics Inc

Changchun Bcht Biotechnology Co Ltd

Chengdu Kanghua Biological Products Co Ltd

Chongqing Zhifei Biological Products Co Ltd

GC Pharma

GlaxoSmithKline Plc

KM Biologics Co Ltd

LG Chem Ltd

Novo Medi Sciences Pvt Ltd

NTxBio LLC

Olymvax Biopharmaceuticals Inc

Panacea Biotec Ltd

Sanofi

Seasons Healthcare Ltd

Serum Institute of India Pvt Ltd

Shantha Biotechnics Pvt Ltd

Sichuan ZehaTimes Pharmaceutical Co Ltd

Stablepharma Ltd

VaxForm LLC

Yisheng Biopharma Co Ltd

Yuxi Jiuzhou Biological Technology Co Ltd

Zhuhai Trinomab Biotechnology Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Tetanus - Overview

Tetanus - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Tetanus - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tetanus - Companies Involved in Therapeutics Development

AIM Vaccine Co Ltd

Beijing Minhai Biotechnology Co Ltd

Beijing Tiantan Biological Products Co Ltd

Biken Co Ltd

Biological E Ltd

BioNet-Asia Co Ltd

Boryung Pharmaceutical Co Ltd

Cadila Healthcare Ltd

CanSino Biologics Inc

Changchun Bcht Biotechnology Co Ltd

Chengdu Kanghua Biological Products Co Ltd

Chongqing Zhifei Biological Products Co Ltd

GC Pharma

GlaxoSmithKline Plc

KM Biologics Co Ltd

LG Chem Ltd

Novo Medi Sciences Pvt Ltd

NTxBio LLC

Olymvax Biopharmaceuticals Inc

Panacea Biotec Ltd

Sanofi

Seasons Healthcare Ltd

Serum Institute of India Pvt Ltd

Shantha Biotechnics Pvt Ltd

Sichuan ZehaTimes Pharmaceutical Co Ltd

Stablepharma Ltd

VaxForm LLC

Yisheng Biopharma Co Ltd

Yuxi Jiuzhou Biological Technology Co Ltd

Zhuhai Trinomab Biotechnology Co Ltd

Tetanus - Drug Profiles

(diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (acellular,adsorbed) + rotavirus + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis + tetanus) (pentavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + haemophilus influenza [serotype B] + meningococcal + pertussis (acellular) + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + haemophilus influenza [serotype B] + pertussis (acellular) + poliomyelitis + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + tetanus) (tetravalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + haemophilus influenzae [serotype B] + pertussis (whole cell) + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (acellular) + tetanus) vaccine 1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (acellular) + tetanus) vaccine 1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (acellular) + tetanus) vaccine 2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (acellular) + tetanus) vaccine 2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (whole cell) + tetanus) (trivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (whole cell) + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis + poliomyelitis + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis + tetanus) (acellular, adsorbed) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + tetanus + pertussis (acellular) + haemophilus influenzae [serotype B]) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + tetanus + pertussis (acellular) + poliomyelitis) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + tetanus + pertussis (acellular)) vaccine 1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + tetanus + pertussis + poliomyelitis + haemophilus influenzae [serotype B]) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Adacel plus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibody for Tetanus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

B-1004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BK-1310 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DTcP vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GC-3111A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KD-370 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LBVD - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NTXV-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tetanus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tetanus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tetanus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tetanus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tetanus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tetanus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TNM-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tetanus - Dormant Projects

Tetanus - Discontinued Products

Tetanus - Product Development Milestones

Featured News & Press Releases

Mar 11, 2019: LG Chem gets $33.4 mil. from Gates Foundation for vaccine development

Aug 02, 2016: CanSino submits a clinical trial application for the component DTP diptheria tetanus pertussis combo vaccine (adults, teenagers and children above 6 years Old)

Sep 01, 2015: Commercialisation of a world changing invention for the stabilisation and delivery of vaccines

Nov 24, 2014: CanSinotech submitted CTA of “Diphtheria and Tetanus Toxoids and Component Pertussis Vaccine Adsorbed” to CFDA

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Tetanus, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Companies, 2021 (Contd..1)

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Products under Development by Companies, 2021 (Contd..2)

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Tetanus – Pipeline by AIM Vaccine Co Ltd, 2021

Tetanus – Pipeline by Beijing Minhai Biotechnology Co Ltd, 2021

Tetanus – Pipeline by Beijing Tiantan Biological Products Co Ltd, 2021

Tetanus – Pipeline by Biken Co Ltd, 2021

Tetanus – Pipeline by Biological E Ltd, 2021

Tetanus – Pipeline by BioNet-Asia Co Ltd, 2021

Tetanus – Pipeline by Boryung Pharmaceutical Co Ltd, 2021

Tetanus – Pipeline by Cadila Healthcare Ltd, 2021

Tetanus – Pipeline by CanSino Biologics Inc, 2021

Tetanus – Pipeline by Changchun Bcht Biotechnology Co Ltd, 2021

Tetanus – Pipeline by Chengdu Kanghua Biological Products Co Ltd, 2021

Tetanus – Pipeline by Chongqing Zhifei Biological Products Co Ltd, 2021

Tetanus – Pipeline by GC Pharma, 2021

Tetanus – Pipeline by GlaxoSmithKline Plc, 2021

Tetanus – Pipeline by KM Biologics Co Ltd, 2021

Tetanus – Pipeline by LG Chem Ltd, 2021

Tetanus – Pipeline by Novo Medi Sciences Pvt Ltd, 2021

Tetanus – Pipeline by NTxBio LLC, 2021

Tetanus – Pipeline by Olymvax Biopharmaceuticals Inc, 2021

Tetanus – Pipeline by Panacea Biotec Ltd, 2021

Tetanus – Pipeline by Sanofi, 2021

Tetanus – Pipeline by Seasons Healthcare Ltd, 2021

Tetanus – Pipeline by Serum Institute of India Pvt Ltd, 2021

Tetanus – Pipeline by Shantha Biotechnics Pvt Ltd, 2021

Tetanus – Pipeline by Sichuan ZehaTimes Pharmaceutical Co Ltd, 2021

Tetanus – Pipeline by Stablepharma Ltd, 2021

Tetanus – Pipeline by VaxForm LLC, 2021

Tetanus – Pipeline by Yisheng Biopharma Co Ltd, 2021

Tetanus – Pipeline by Yuxi Jiuzhou Biological Technology Co Ltd, 2021

Tetanus – Pipeline by Zhuhai Trinomab Biotechnology Co Ltd, 2021

Tetanus – Dormant Projects, 2021

Tetanus – Dormant Projects, 2021 (Contd..1)

Tetanus – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Tetanus, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Targets, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports